EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

Yi-Long Wu iD, Maximilian Hochmair, Yi Yang, Xue-Ning Yang, Masahiro Tsuboi, Luis Paz-Ares, James Chih-Hsin Yang, Lin Wu, Hye Ryun Kim, Damian T Rieke, Melissa Johnson, Benjamin Besse iD und 8 weitere

New England Journal of Medicine · 13.08.2026 · 395 (7) · 660-670

DOI: 10.1056/nejmoa2602628 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.08.2026. Verfasst von Yi-Long Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzho…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-retPyrazolesPyridinesNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantDouble-Blind MethodKaplan-Meier EstimateNeoplasm StagingOncogene Proteins, FusionProgression-Free SurvivalFollow-Up StudiesDisease ProgressionAged, 80 and over

Substanzen

Antineoplastic AgentsOncogene Proteins, FusionProto-Oncogene Proteins c-retPyrazolesPyridinesRET protein, humanselpercatinib

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
  • Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna.
  • Department of Thoracic Surgery, Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Third People's Hospital of Chengdu, Chengdu, China.
  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid.
  • National Taiwan University Hospital, NTU Cancer Center, Taipei.

ORCID-Profile: Yi-Long Wu, Benjamin Besse, Jonathan Goldman

Förderung

  • Eli Lilly and Company

Zitieren

APA

Wu, Y. L., Hochmair, M., Yang, Y., Yang, X. N., Tsuboi, M., Paz-Ares, L., Yang, J. C., Wu, L., Kim, H. R., Rieke, D. T., Johnson, M., Besse, B., Sharma, N., Maeda, P., Peterson, P., Lin, B. K., Frimodt-Moller, B., Goldman, J., Drilon, A., & LIBRETTO-432 Trial Investigators (2026). Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 395(7), 660-670. https://doi.org/10.1056/nejmoa2602628

Vancouver

Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, et al. Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(7):660-670. doi:10.1056/nejmoa2602628

BibTeX
@article{Wu2026,
  author = {Wu, Yi-Long and Hochmair, Maximilian and Yang, Yi and Yang, Xue-Ning and Tsuboi, Masahiro and Paz-Ares, Luis and Yang, James Chih-Hsin and Wu, Lin and Kim, Hye Ryun and Rieke, Damian T and Johnson, Melissa and Besse, Benjamin and Sharma, Nivedita and Maeda, Patricia and Peterson, Patrick and Lin, Boris Kin and Frimodt-Moller, Bente and Goldman, Jonathan and Drilon, Alexander and LIBRETTO-432 Trial Investigators, LIBRETTO-432 Trial Investigators},
  title = {Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {7},
  pages = {660--670},
  doi = {10.1056/nejmoa2602628}
}
Kostenlos starten →